Last
Update:
February 19, 2018
Documents identified with this icon are in Portable Document Format (PDF)
and require the
Adobe
Acrobat Reader
| |
Impact
of ritonavir dose and schedule on CYP3A inhibition and venetoclax clinical
pharmacokinetics.
Freise KJ, Hu B, Salem AH.
Eur J Clin Pharmacol.
2018 Jan 4
Abstract
FULL-TEXT ARTICLE
Long-term
effectiveness of initiating non-nucleoside reverse transcriptase inhibitor-
versus ritonavir-boosted protease inhibitor-based antiretroviral therapy:
implications for first-line therapy choice in resource-limited settings.
Lima VD, Hull M, McVea D,
et al
J Int AIDS Soc. 2016 Aug 5;19(1):20978.
Paper
FULL-TEXT ARTICLE
Response to First-Line Ritonavir-Boosted Protease Inhibitors (PI/r)-Based
Regimens in HIV Positive Patients Presenting to Care with Low CD4 Counts:
Data from the Icona Foundation Cohort.
d'Arminio Monforte A, Cozzi-Lepri A, Maggiolo F, et al
PLoS One. 2016 Jun
27;11(6):e0156360.
Paper
FULL-TEXT ARTICLE
Effectiveness of Ritonavir-Boosted Protease Inhibitor Monotherapy in
Clinical Practice Even with Previous Virological Failures to Protease
Inhibitor-Based Regimens.
López-Cortés LF, Castaño MA, López-Ruz
MA, et al
PLoS One.
2016 Feb 12;11(2):e0148924.
Paper
Late treatment failures in cerebrospinal fluid in patients on long-term
maintenance ART with ritonavir-boosted protease PI monotherapy.
Kahlert C, Bregenzer A, Gutmann C, et al
Infection. 2015 Dec 11
Abstract
Potential association between rosuvastatin use and high atazanavir trough
concentrations in ritonavir-treated HIV-infected patients.
Gervasoni C, Riva A,
Rizzardini G, et al
Antivir Ther.
2014 Oct 3.
Abstract
Characterization of Ritonavir-Mediated Inactivation of Cytochrome
P450 3A4.
Rock BM, Hengel SM, Rock DA, et al
Mol Pharmacol. 2014 Oct 1
Abstract
Investigating the contribution of CYP2J2 to ritonavir metabolism in vitro and in
vivo.
Kaspera R, Kirby BJ, Sahele T,
et al
Biochem Pharmacol. 2014 Jun
25.
Abstract
FULL-TEXT ARTICLE
Moving Away from Ritonavir, Abacavir, Tenofovir, and Efavirenz (RATE) - Agents
That Concern Prescribers and Patients: A Feasibility Study and Call for a Trial.
Achhra AC, Boyd MA, Law MG,
et al
PLoS One.
2014 Jun 26;9(6):e99530.
Paper
Intracellular antiviral activity of low-dose
ritonavir in boosted protease inhibitors regimens.
De Nicolò A, Simiele M, Calcagno A, et al
Antimicrob Agents Chemother.
2014 May 5
Abstract
Ritonavir Analogues As A Probe For Deciphering The Cytochrome P450 3A4
Inhibitory Mechanism.
Sevrioukova IF, Poulos TL.
Curr Top Med Chem.
2014
May 6.
Abstract
Identifying the optimal dose of ritonavir in the treatment of
malignancies.
Moawad EY.
Metab Brain Dis. 2013 Nov 19.
Abstract
In HIV/hepatitis C virus co-infected patients, higher
25-hydroxyvitamin D concentrations were not related to hepatitis C virus
treatment responses but were associated with ritonavir use.
Branch AD, Kang M, Hollabaugh K,
et al
Am J Clin Nutr. 2013 Jun 5
Abstract
Time-dependent interaction of ritonavir in chronic use: The
power balance between inhibition and induction of P-glycoprotein and
cytochrome P450 3A.
Fukushima K, Kobuchi S, Mizuhara
K, et al
J Pharm Sci.
2013 Apr 15.
Abstract
Discordant Associations Between SLCO1B1 521T→C and Plasma Levels of
Ritonavir-boosted Protease Inhibitors in AIDS Clinical Trials Group Study
A5146.
Zhang X, Tierney C,
Albrecht M, et al
Ther Drug Monit.
2013 Apr;35(2):209-216.
Abstract |
The Antiretroviral Protease Inhibitor Ritonavir Accelerates Glutathione Export
from Cultured Primary Astrocytes.
Arend C, Brandmann M, Dringen R.
Neurochem Res. 2013 Jan
23
Abstract |
RP-HPLC separation and characterization of unknown impurities of
a novel HIV-protease inhibitor Darunavir by ESI-MS and 2D NMR spectroscopy.
Nageswara Rao R, Ramachandra B, Santhakumar K.
J Pharm Biomed Anal. 2012 Nov
29;75C:186-191
Abstract
Intracellular accumulation of ritonavir combined with different
protease inhibitors and correlations between concentrations in plasma and
peripheral blood mononuclear cells.
D'Avolio A, Simiele M, Calcagno A,
et al
J Antimicrob Chemother. 2012 Dec 5
Abstract |
Injecting
epidural and intra-articular triamcinolone in HIV-positive patients on
ritonavir: beware of iatrogenic
Cushing's syndrome.
Maviki M, Cowley P,
Marmery H.
Skeletal
Radiol.
2012 Nov 15.
Abstract
MIA-QSAR modeling of the anti-HIV-1 protease activities and
cytotoxicities of Ritonavir analogs.
Silva DG, Freitas MP.
Curr Drug Saf. 2012 Oct 9.
Abstract |
Secondary Patenting Of Branded
Pharmaceuticals: A Case Study Of How Patents On Two HIV
Drugs
Could Be Extended For Decades.
Amin T, Kesselheim AS.
Health Aff (Millwood).
2012 Oct;31
Abstract
Boosting of HIV Protease Inhibitors by Ritonavir in the Intestine: The
Relative Role of Cyp and P-gp
Inhibition Based on Caco-2 monolayers Versus In Situ Intestinal
Perfusion in Mice.
Holmstock NF, Annaert PP, Augustijns P.
rug
Metab Dispos.
2012 May 1
Abstract
Ritonavir or saquinavir impair the invasion of cervical
intraepithelial neoplasia cells via a reduction of MMP
expression and activity.
Barillari G, Iovane A, Bacigalupo I,
et al
AIDS. 2012 Feb 4.
Abstract |
Ritonavir stimulates foam cell formation by activating
PKC.
Xiang J, Sun G, Mu Y,
et al
Chem Biol Interact. 2011 Oct 12.
Abstract |
Synthesis and antimycobacterial activity of novel amino
alcohols containing central core of the
anti-HIV drugs Lopinavir and Ritonavir.
Gomes CR, Moreth M, Cardinot D, et al
Chem Biol Drug Des.
2011 Sep 20.
Abstract
Ritonavir inhibits the two main prasugrel bioactivation pathways in
vitro:
a potential drug-drug interaction in HIV patients.
Daali Y, Ancrenaz V, Bosilkovska M,
et al
|
Metabolism.
2011 May 5.
Abstract
Heat-stable ritonavir tablets: a new formulation of a
pharmacokinetic enhancer for HIV.
Sherman EM, Steinberg JG.
Expert Opin Pharmacother. 2010 Dec 10.
Abstract
|
Micellar electrokinetic chromatography method development for determination of
impurities in Ritonavir.
Carvalho AZ, El-Attug MN, Zayed SE, et al
J Pharm Biomed Anal. 2010
Aug 16.
Abstract |
Postprandial lipid effects of low-dose ritonavir vs. raltegravir
in HIV-uninfected adults.
Samaras K, Richardson R, Carr A.
AIDS. 2010 Jul 17;24(11):1727-31
Abstract |
Investigation of low-dose ritonavir on human peripheral blood mononuclear cells
using
gene expression whole genome microarrays.
Yilmaz S, Boffito M, Collot-Teixeira S, et al
Genomics. 2010
Jul;96(1):57-65.
Abstract |
Boosting Dose Ritonavir Does Not Alter Peripheral Insulin Sensitivity in Healthy
HIV-Seronegative Volunteers.
Taylor SA, Lee GA, Pao VY,
et al
J Acquir Immune Defic Syndr.
2010 Jun 30.
Abstract |
Protease inhibitors atazanavir, lopinavir and ritonavir are potent
blockers, but
poor substrates, of ABC transporters in a broad panel of ABC
transporter-
overexpressing cell lines.
Bierman WF, Scheffer GL, Schoonderwoerd A, et al
J Antimicrob Chemother.
2010 Jun 15
Abstract |
Effect of ritonavir and atazanavir on human subcutaneous preadipocyte
proliferation
and differentiation.
Caso G, Mileva I, McNurlan MA,
et al
Antiviral Res.
2010 Feb 10
Abstract
|
How much ritonavir is needed to boost protease inhibitors? Systematic review of
17
dose-ranging pharmacokinetic trials.
Hill A, van der Lugt J, Sawyer W, Boffito M.
AIDS.
2009 Oct 3.
Abstract |
Mutation T74S in HIV-1 subtype B and C proteases resensitizes them to
ritonavir and
indinavir and confers fitness advantage.
Soares EA, Santos AF, Gonzalez LM, et al
J Antimicrob Chemother.
2009 Aug 26.
Abstract |
HIV monotherapy with ritonavir-boosted protease inhibitors: a
systematic review.
Bierman WF, van Agtmael MA, Nijhuis M,
et al
AIDS.
2008 Dec 24.
Abstract
|
Effects of the ritonavir price increase on the cost of
protease inhibitor regimens in United States.
Lee WC, Williams KW, Chen E, et al
Manag Care
Interface. 2006 Mar;19(3):27-32
Abstract
|
| |
Altered pharmacokinetics and pharmacodyamics of
repaglinide by ritonavir in rats with healthy, diabetic and
impaired hepatic function.
Goud T, Maddi S, Nayakanti D,
Thatipamula RP.
Drug Metabol Personal Ther.
2016 May 11
Abstract
Ritonavir inhibits intratumoral docetaxel
metabolism and enhances docetaxel antitumor activity in an
immunocompetent mouse breast cancer model.
Hendrikx JJ, Lagas JS, Song JY, et
al
Int
J Cancer. 2015 Aug 21.
Abstract
Role of maraviroc in a dyslipidemic murine model
of atherosclerosis RTV-induced.
Cipriani S, Mencarelli A, Francisci D, et al
J Int AIDS Soc. 2012 Nov
11;15(6):18154.
Abstract
Nordihydroguaiaretic acid (NDGA) inhibits ritonavir-induced
endothelial dysfunction in porcine
pulmonary arteries.
Lü JM, Nurko J, Jiang J, et a
Med Sci Monit.
2011 Oct 26;17(11):BR312-318.
Abstract
Natural antioxidant dihydroxybenzyl alcohol blocks
ritonavir-induced endothelial dysfunction in
porcine pulmonary arteries and human endothelial cells.
Weakley
SM, Jiang J, Lu J, et al.
Med Sci Monit. 2011 Aug
22;17(9):BR235-241.
Abstract
UPLC-MS/MS quantification of nanoformulated
ritonavir, indinavir, atazanavir, and efavirenz in
mouse serum and tissues.
Huang J, Gautam N, Bathena SP
J
Chromatogr B Analyt Technol Biomed Life Sci. 2011 Jul
1
Abstract
HIV-1 Protease Inhibitor, Ritonavir: A Potent Inhibitor of CYP3A4,
Enhanced the
Anticancer Effects of
Docetaxel in Androgen-Independent Prostate Cancer Cells In
vitro and In
vivo.
Ikezoe T, Hisatake Y, Takeuchi T, et al
Cancer Res. 2004 Oct 15;64(20):7426-31
Abstract
|
Low Systemic Exposure of Oral Docetaxel in Mice
Resulting from Extensive
First-Pass
Metabolism Is Boosted by
Ritonavir.
Bardelmeijer HA, Ouwehand M, Buckle T, et al.
Cancer Res 2002 Nov 1;62(21):6158-6164
Abstract
Pharmacokinetic interactions between HIV-1 protease inhibitors in rats: study
on
combinations
of two kinds of HIV-1 protease inhibitors
Shibata N,
Matsumura Y,
Okamoto H, et al.
J
Pharm Pharmacol 2000 Oct;52(10):1239-46
Abstract |
|
|
General
Reports
Perinatal
Data
